UBS Group AG Boosts Stake in Natus Medical Incorporated (BABY)

UBS Group AG boosted its stake in shares of Natus Medical Incorporated (NASDAQ:BABY) by 86.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,908 shares of the medical equipment provider’s stock after buying an additional 34,753 shares during the period. UBS Group AG’s holdings in Natus Medical were worth $2,940,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new position in Natus Medical during the first quarter valued at approximately $110,000. Victory Capital Management Inc. increased its position in Natus Medical by 94.0% in the first quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 1,543 shares in the last quarter. State of Alaska Department of Revenue increased its position in Natus Medical by 1.7% in the first quarter. State of Alaska Department of Revenue now owns 3,630 shares of the medical equipment provider’s stock valued at $142,000 after buying an additional 60 shares in the last quarter. San Francisco Sentry Investment Group CA bought a new position in shares of Natus Medical during the first quarter worth about $216,000. Finally, Ladenburg Thalmann Financial Services Inc. increased its position in shares of Natus Medical by 6.5% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,320 shares of the medical equipment provider’s stock worth $220,000 after buying an additional 384 shares during the period. Hedge funds and other institutional investors own 93.32% of the company’s stock.

Shares of Natus Medical Incorporated (NASDAQ:BABY) traded down 1.81% during trading on Friday, hitting $35.20. The stock had a trading volume of 378,665 shares. Natus Medical Incorporated has a 52 week low of $33.15 and a 52 week high of $44.39. The firm has a 50-day moving average price of $36.69 and a 200 day moving average price of $36.94. The company has a market capitalization of $1.14 billion, a PE ratio of 61.86 and a beta of 0.95.

Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The company had revenue of $122.20 million during the quarter, compared to analyst estimates of $121.99 million. During the same quarter in the previous year, the company posted $0.39 EPS. Natus Medical’s revenue for the quarter was up 27.3% on a year-over-year basis. Equities analysts anticipate that Natus Medical Incorporated will post $1.70 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “UBS Group AG Boosts Stake in Natus Medical Incorporated (BABY)” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/07/30/ubs-group-ag-increases-stake-in-natus-medical-incorporated-baby-updated-updated-updated.html.

A number of equities analysts have recently issued reports on BABY shares. Zacks Investment Research upgraded Natus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, April 4th. Benchmark Co. restated a “buy” rating and set a $48.00 price objective (down from $55.00) on shares of Natus Medical in a research report on Monday, May 1st. TheStreet downgraded Natus Medical from a “b” rating to a “c+” rating in a research report on Thursday, April 27th. Finally, BidaskClub upgraded Natus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, July 1st. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $45.00.

In other Natus Medical news, insider James B. Hawkins purchased 4,000 shares of the stock in a transaction on Thursday, June 15th. The stock was acquired at an average price of $33.98 per share, with a total value of $135,920.00. Following the transaction, the insider now directly owns 578,023 shares of the company’s stock, valued at approximately $19,641,221.54. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Doris Engibous sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $32.68, for a total value of $163,400.00. Following the transaction, the director now directly owns 22,650 shares of the company’s stock, valued at approximately $740,202. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply